CD79A and glomerulonephritis: We speculate that the reason there is no difference is because the different treatments in our research were chosen according to the clinical symptoms, such as persistent nephrotic syndrome, rather than pathological features such as the presence or absence of IgA deposition, which is also recommended by the KDIGO clinical practice guidelines for glomerulonephritis of IMN16.